Patents Assigned to SHENZHEN KANGJUZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD
  • Patent number: 10711005
    Abstract: Compound I and a compound II as well as preparation methods therefor and use thereof are disclosed. A newly synthesized compound of formula I is capable of stimulating congenital immunity and cellular immunity for tumor resistance while greatly improving the antitumor effect of ethacrynic acid (EA), and thus an integrated synergistic anti-tumor dual-immunity drug design is explored. The immune response mechanism for resisting melanoma of the compound as shown in the formula I is demonstrated. A compound that is as shown in a formula II and is prepared from the compound of formula I and ROR1 by means of covalency markedly slows down the growth of subcutaneously transplanted mammary cancer tumor, such that the immune response mechanism, for treating the mammary cancer, of the compound as shown in the formula II is demonstrated.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: July 14, 2020
    Assignees: SHENZHEN UNIVERSITY, SHENZHEN KANGJUZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Guangyi Jin, Zhulin Wang
  • Publication number: 20180339987
    Abstract: Compound I and a compound II as well as preparation methods therefor and use thereof are disclosed. A newly synthesized compound of formula I is capable of stimulating congenital immunity and cellular immunity for tumor resistance while greatly improving the antitumor effect of ethacrynic acid (EA), and thus an integrated synergistic anti-tumor dual-immunity drug design is explored. The immune response mechanism for resisting melanoma of the compound as shown in the formula I is demonstrated. A compound that is as shown in a formula II and is prepared from the compound of formula I and ROR1 by means of covalency markedly slows down the growth of subcutaneously transplanted mammary cancer tumor, such that the immune response mechanism, for treating the mammary cancer, of the compound as shown in the formula II is demonstrated.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 29, 2018
    Applicants: SHENZHEN UNIVERSITY, SHENZHEN KANGJUZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Guangyi JIN, Zhulin WANG
  • Patent number: 10030066
    Abstract: Disclosed is an immune receptor modifier conjugate, obtained from the reaction between a coupling precursor and a biotic ligand, the coupling precursor being a 9-position aminomethyl benzyl purine biotic coupling precursor, and the biotic ligand being selected from one or more of polypeptide, protein, glycoprotein, polysaccharide, polynucleotide, inactivated cells and inactivated microbes. The immune receptor modifier couplet can be used for immunomodulation, antibody preparation, anti-virus, diabetes, tumor immunomodulation, and tumor bio-immunotherapy. The conjugate compounds or salts thereof can be prepared into various therapeutic drugs, and can be prepared into a compound drug together with other drugs, or pharmaceutically acceptable carrier composites or conjugates. Also disclosed are compounds for synthesizing the coupling precursor and salts thereof.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 24, 2018
    Assignees: SHENZHEN UNIVERSITY, SHENZHEN KANGJUZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD
    Inventors: Guangyi Jin, Zhulin Wang